ScripBristol Myers Squibb obtained two US Food and Drug Administration approvals during the week of 7 April for combination therapy with its immuno-oncology stalwarts Opdivo (nivolumab) and Yervoy (ipilimu
ScripThe number of drug candidates in the pipeline in 2024 rose by its lowest rate so far this decade, with the total at the turn of the year hitting 23,875. The 4.60% increase over 2024’s pipeline figure
ScripIt looks as though nothing will come of the takeover talks PureTech Health has held with Nordic Capital Epsilon but there is a compelling argument for taking its ‘hub-and-spoke’ business private in th
ScripRoche has unveiled promising Phase Ib/IIa trial results suggesting its “brain shuttle” Alzheimer’s disease candidate trontinemab could be safer and more effective than approved therapies, and will beg